132 related articles for article (PubMed ID: 35848518)
1. Induction therapy in lung transplantation: A contemporary analysis of trends and outcomes.
Shagabayeva L; Osho AA; Moonsamy P; Mohan N; Li SS; Wolfe S; Langer NB; Funamoto M; Villavicencio MA
Clin Transplant; 2022 Nov; 36(11):e14782. PubMed ID: 35848518
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
[TBL] [Abstract][Full Text] [Related]
3. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
4. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
5. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Basiliximab and Anti-Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis.
Ansari D; Höglund P; Andersson B; Nilsson J
J Am Heart Assoc; 2015 Dec; 5(1):. PubMed ID: 26722127
[TBL] [Abstract][Full Text] [Related]
7. Induction Therapy for Lung Transplantation in COPD: Analysis of the UNOS Registry.
Duffy JS; Tumin D; Pope-Harman A; Whitson BA; Higgins RS; Hayes D
COPD; 2016 Oct; 13(5):647-52. PubMed ID: 26829054
[TBL] [Abstract][Full Text] [Related]
8. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data.
Cai J; Terasaki PI
Transplantation; 2010 Dec; 90(12):1511-5. PubMed ID: 21057388
[TBL] [Abstract][Full Text] [Related]
9. Induction therapy in renal transplant recipients: how convincing is the current evidence?
Wagner SJ; Brennan DC
Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
[TBL] [Abstract][Full Text] [Related]
10. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
[TBL] [Abstract][Full Text] [Related]
11. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
Deeks ED; Keating GM
Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction in renal transplantation.
Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
[TBL] [Abstract][Full Text] [Related]
13. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
14. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
[TBL] [Abstract][Full Text] [Related]
15. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab.
Ansari D; Lund LH; Stehlik J; Andersson B; Höglund P; Edwards L; Nilsson J
J Heart Lung Transplant; 2015 Oct; 34(10):1283-91. PubMed ID: 26087667
[TBL] [Abstract][Full Text] [Related]
16. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of Basiliximab and Alemtuzumab induction therapies in blood type A2-to-B kidney transplantation: Impact on kidney function and de novo donor-specific HLA antibodies.
Hanouneh T; Attieh RM; Craver E; Jebrini A; Elrefaei M; Jarmi T
Transpl Immunol; 2023 Dec; 81():101958. PubMed ID: 37949378
[TBL] [Abstract][Full Text] [Related]
18. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants.
Hafeez MS; Haq MU; Bakhthiyar SS; Azhar K; Awan AAY; Ramana Murthy BV; Abbas R
Transpl Immunol; 2022 Dec; 75():101733. PubMed ID: 36347493
[TBL] [Abstract][Full Text] [Related]
20. Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience.
Jarmi T; Abdelmoneim Y; Li Z; Jebrini A; Elrefaei M
Transpl Immunol; 2023 Apr; 77():101778. PubMed ID: 36584928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
